` ATNM (Actinium Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

A
ATNM
vs
S&P 500

Over the past 12 months, ATNM has significantly outperformed S&P 500, delivering a return of +36% compared to the S&P 500's +14% growth.

Stocks Performance
ATNM vs S&P 500

Loading
ATNM
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ATNM vs S&P 500

Loading
ATNM
S&P 500
Difference
www.alphaspread.com

Performance By Year
ATNM vs S&P 500

Loading
ATNM
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Actinium Pharmaceuticals Inc vs Peers

S&P 500
ATNM
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Actinium Pharmaceuticals Inc
Glance View

Market Cap
52.7m USD
Industry
Biotechnology

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The firm develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).

ATNM Intrinsic Value
Not Available
A
Back to Top